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Primary immunodeficiencies (PIDs) are genetic disorders of the immune system comprising many different phe-
notypes. Although previously considered rare, recent advances in their clinical, epidemiological, and molecular
definitions are revealing how much we still need to learn about them. For example, geographical and ethnic vari-
ations as well as the impact of certain practices influence their frequency and presentation, making it necessary to
consider their study in terms of regions. The LatinAmerican Society for Immunodeficiencies was established as an or-
ganization dedicated to provide scientific support for basic and clinical research and to develop tools and educational
resources to promote awareness in the medical community. Initiatives such as these are positively influencing the
way PIDs are tackled in these countries, as shown by recent reports and publications. This paper provides a historical
compilation and a current view of the many issues faced by scientists studying these diseases in these countries,
highlighting the diverse scientific contributions and offering a promising perspective for the further developments
in this field in Latin America.
Keywords: primary immunodeficiency; Latin America; LASID; immunodeficiency epidemiology; PID registry; Latin
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Introduction
Primary immunodeficiencies (PIDs) are inborn er-
rors of the immune system currently comprising
almost 200 different phenotypes that predispose
affected individuals not only to recurrent infec-
tions but also to chronic and systemic inflamma-
tion, hypersensitivity reactions, autoimmunity, and
cancer.1,2 Their frequency in the general popula-
tion is approximately 1:2,500 live newborns, and
their global prevalence is currently unknown but
is estimated to vary from 1:5,000 to 1:500,000 de-
pending on the specific disease and the population
under study.3–5 The International Union of Im-
munological Societies (IUIS) Expert Committee
for Primary Immunodeficiency currently classifies
PIDs in eight groups based on the affected immune
component and the genetic defect.3 These groups
range from well-recognized antibody and comple-
ment deficiencies (and the combined cellular and
phagocyte defects), to recently added categories that
include diseases of immune regulation, innate im-
munity, and autoinflammatory syndromes, and to
themore complex well-defined syndromes with im-
munodeficiency. This classification is updated every
twoyears to adjust for the continuous and rapid evo-
lution of the field, as advances in biological sciences
and biotechnology are revealing new insights into
the nature of PIDs and their actual contribution to
human pathology.
Better tools for early diagnosis, such as neona-
tal screening with T cell receptor excision circles
(TRECS) and Kappa-deleting recombination ex-
cision circles (KRECS), and even the possibility
doi: 10.1111/j.1749-6632.2011.06289.x
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of having an entire genome sequenced in a cost-
effective manner, are influencing our ability to re-
duce the morbidity and mortality related to these
diseases. There is the hope that these advances will
help us to circumvent the complications and seque-
lae that are so common to patients with a PID by
reducing disabilities related to school and/or work
attendance, improving productive capacity, and de-
creasing costs to health care systems.6,7
Proper knowledge of PIDs remains relatively
scarce among medical communities in many coun-
tries around the globe, reflecting, in some cases,
lack of awareness and in other cases apathy, as the
field of immunology is often mistakenly considered
too complicated to be useful for daily practice. In
addition, health authorities in these countries are
poorly informed and often underestimate the epi-
demiologic, social, and economic impact of PIDs
compared to other more common diseases, making
it more difficult for physicians working in this field
to provide quality care for patients.
Delay in diagnosis of PIDs, as a consequence of
lack of knowledge about them, is evident in coun-
tries of disadvantaged regions; but interestingly it
also occurs in developed countries. Thus, research
of and education in PIDs must be implemented as a
public health policy universally, since the prognosis
ofmany patients can be improved by early diagnosis
and appropriate access to care and treatment.7,8 In
general, when evaluating a patient for a suspected
PID, the assessment of the immune system can be
performed with inexpensive, simple, and reliable
tests. Under specific circumstances, however, this
might requiremore sophisticated and expensive lab-
oratory tests,withdelay indiagnosis oftenassociated
with limited access to these specialized resources.9,10
For example, in Finland, the diagnosis of common
variable immunodeficiency (CVID) was delayed by
5 years in two-thirds of the patients and by 10 years
in one-third of them.11 In the United Kingdom, a
delay of 6.2 years evident between 1989 and 1995
decreased to 3.5 years after the implementation of a
government program directed at early recognition
and diagnosis of PIDs.12
One possibility for establishing diagnostic perfor-
mance tools for certain diseases is to evaluate patient
registrationdata.Registries are designed to study the
behavior of diseases in certain populations, and they
are also very useful for improving patient care by
providing epidemiological data that helps to mon-
itor health policies. In Europe, the PID registry is
carried out by the European Society for Immun-
odeficiencies (ESID) (http://www.esid.org/), a non-
governmental organization that emerged in 1994 to
promote the exchange of information among doc-
tors, nurses, investigators, patients, and their fami-
lies.13–16 ESID continuously receives data from 85
specialized centers, and their entries in 2011 in-
cluded 14,506 patients, implying an approximate
prevalence of 4–47/1,000,000.16,17
The Latin American Group for Immunodeficien-
cies (LAGID) was created in 1993 to study preva-
lence and to promote awareness about PIDs inMex-
ico andCentral and SouthAmerica. In 2009, LAGID
became the Latin American Society for Immunode-
ficiencies (LASID) and established an online reg-
istry (http://imunodeficiencia.unicamp.br:8080/).
The progress of PID registry in Latin America is
shown in Table 1 and currently includes 1,888 cases,
since April 2009.
Early and proper diagnosis and access to treat-
ments remain the main problems that PID pa-
tients face in Latin America. These can be partly
explained by the lack of proper training of gen-
eral practitioners and medical specialists (mainly
pediatricians), leading to misdiagnosis or late di-
agnosis. However, there are also difficulties in ac-
cessibility to screening tests, educational programs,
and treatment centers.18–20 Therefore, special pro-
grams and focused policies must be implemented
with the support of governments to overcome these
difficulties.
PID diagnosis, treatment, and education in
Latin America
Argentina
The main diagnostic centers in Argentina are pub-
lic and located in Buenos Aires, and there are other
less specialized centers in La Plata, Rosario, Cor-
doba, andMendoza; they are all accessible at no cost.
Private hospitals in Argentina only offer limited di-
agnosis because they do not have specialized labora-
tories and professionals dedicated to PIDs. In addi-
tion, patients from Paraguay, Bolivia, and Uruguay
are usually diagnosed and treated in Buenos Aires
since these countries have few resources.21 Regard-
ing treatment, patients with PIDs who are in need
of intravenous immunoglobulin (IVIG) are usu-
ally sent to Buenos Aires; however, infusions are
often discontinued once pediatric patients become
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Table 1.Participating countries in the LASID PID registry program
July December July December May September
Countries 2009 2009 2010 2010 2011 2011
Argentina 2 45 178 229 456 700
Brazil 201 257 319 385 470 539
Chile 2 5 11 12 17 31
Colombia 87 127 136 136 136 204
Costa Rica 0 0 0 0 72 94
Honduras 0 9 10 10 11 32
Mexico 12 42 163 194 231 250
Paraguay 0 0 0 1 1 2
Peru 0 0 0 10 11 24
Uruguay 0 0 0 1 1 5
Venezuela 0 0 0 0 3 7
Total 304 485 818 978 1,409 1,888
LASID progress since start. From July 2009 until September 2011, LASID registered 1,888 cases from 12 countries.
adults.22 One issue that further complicates the pic-
ture is that in Argentina immunologists are not rec-
ognized as specialists by theMinistry of Health, and
only two hospitals in Buenos Aires offer training in
immunology.19,23 To partly overcome these prob-
lems, this year, the JeffreyModell Foundation estab-
lished a diagnostic center at the Hospital “Ricardo
Gutierrez” in Buenos Aires, to provide PID patient
management, stimulate patients’ social and educa-
tional activities, and disseminate a national medical
education program on PIDs.
Brazil
It is estimated that Brazil has 2,000 PID patients
under treatment and that approximately 18,000 pa-
tients with PIDs are still waiting for diagnosis and
proper management.24 Immunological diagnosis is
supported by several centers located in Sa˜o Paulo,
Minas Gerais, Parana´, Rio Grande do Sul, Bahia,
and Rio de Janeiro.19,24,25 Centers in the south-
east region of the country have specialized pro-
fessionals with structure and access to molecular
and genetic diagnosis. In Brazil, the federal gov-
ernment covers patients’ referrals to specialized
centers when necessary.26–28 Still, high cost and
poor access to specialized laboratories are consid-
ered by doctors to be the major problems in the
diagnosis of PID (results available at http://www.
bragid.org.br/download/graficos.pps). Highly spe-
cialized PID diagnostic centers in Brazil are sup-
ported by the Ministry of Health and the gov-
ernment research agencies Fundac¸a˜o de Amparo
a` Pesquisa do Estado de Sa˜o Paulo (FAPESP) and
Conselho Nacional de Desenvolvimento Cientı´ficio
e Tecnolo´gico (CNPq), and recently by the Jeffrey
Modell Foundation.
The Brazilian Group of Primary Immunodefi-
ciencies was established in 1997. Activities of this
group take place in parallel with those of LASID and
the Brazilian Society of Allergy and Immunopathol-
ogy (ASBAI), including the first and second
LASID Summer Schools, the implementation of
the online LASID registry (http://imunodeficiencia.
unicamp.br:8080/), two LASID scientific meetings,
and a continuous medical education (CME) pro-
gram throughout the country. The Federal Univer-
sity of Sa˜o Paulo-UNIFESP, in partnership with the
Jeffrey Modell Foundation, created the first Jeffrey
Modell Diagnostic Center for PID in Latin Amer-
ica in April 2009 to enable physicians to diagnose
and treat patients earlier, and to promote patient
social activities and education. In Brazil, there are
numerous funded residency programs in allergy and
immunology, although only few centers train pro-
fessionals in PID, mostly in the southeast region of
the country.19,25
A pilot program for newborn screening for se-
vere combined immunodeficiency (SCID), T cell
deficiencies, and DiGeorge syndrome began in
2010 at the Institute of Biomedical Sciences at the
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University of Sa˜o Paulo, in cooperation with the
FederalUniversity of Sa˜oPauloMedical School. This
program, screening all newborns froma large public
hospital in the city of Sa˜o Paulo, is expected to run
for at least three years.
Bacillus Calmette-Gue´rin (BCB) is a mandatory
vaccine for tuberculosis given to all newborns in
Brazil. The city of Sa˜o Paulo reports approximately
80 cases per year of BCG-adverse reactions that
require specific antibiotic therapy. This motivated
professionals from both of the above universities to
start a second pilot PID screening programbased on
the investigation of PIDs in all patients presenting
with BCG-adverse reactions requiring antibiotics.
CNPq, FAPESP, and Baxter Bioscience, are sup-
porting both projects. The newborn screening pro-
gram, together with the study of PIDs in patients
with BCG-adverse reactions in the city of Sa˜o
Paulo—a large Latin American urban center of ap-
proximately 20 million inhabitants—should pro-
vide useful information about some of the most
relevant PIDs in the first year of life.
Chile
Laboratories for diagnosis of PIDs inChile are avail-
able in Santiago, Temuco, Valparaiso, and Con-
cepcio´n. Basic screening tests for PIDs can be per-
formed in large hospitals, although they receive little
government financial support.29 As in most devel-
oping countries in Latin America, the diagnosis of
PID is often suspected and performed only after pa-
tients have suffered numerous infections and failed
treatments, leading to their referral to an infectious
diseases clinic or other specialists, and finally to an
immunology center. Chile has a three-year medical
residency program in immunology at theUniversity
of Santiago, providing training and care for adult
and pediatric patients.19 The Jeffrey Modell Foun-
dation also established a network in Chile in 2010
with similar goals to advance the PID field in this
country. An advancedmolecular diagnostic center is
under construction at the University of La Frontera
in Temuco, which is intended to take care of most
of the molecular genetic diagnoses in Chile.
Colombia
InColombia, several cities such asMedellin, Bogota´,
Cali, and others, have well-equipped clinical labo-
ratories that are able to perform tests for screening
of common PIDs, but highly specific and special-
ized tests in immunology, molecular biology, and
genomics are only available at the only national PID
referral center located in the University of Antio-
quia in Medellin.30,31 The national PID registry is
carried out by this center and, interestingly, it shows
that about 80% of PID cases come from the state of
Antioquia,30,32 although this territory harbors less
than20%of theColombianpopulation.This reflects
a distortion in the distribution of diagnosed cases
in this country. To circumvent this problem, this re-
ferral center has established a network of physicians
in other major cities, and is providing assistance for
the development of other specialized centers and
programs connected in a network in Bogota, Cali,
Cartagena, and other cities around the country.
In Colombia, every citizen is entitled to a ba-
sic health plan that is subsidized by the govern-
ment (the Plan Obligatorio de Salud (POS)) and
that provides basic coverage for most diseases in-
cluding PIDs.33,34 To get additional health cover-
age, however, people are required to buy health
plans that are available through private health care
providers. Most patients in need of IVIG get their
treatment from their respective health care provider
at no cost as the cost is refunded through a govern-
mentnational fund (fondode solidaridadyGarantia
(FOSYGA)). In terms of awareness and educa-
tion, the national patient organizationDianaGarcia
de Olarte Primary Immunodeficiency Foundation
(FIP) supports and develops educational programs,
provides professional advice for IVIG treatments
in specialized centers, and offers legal advice for pa-
tients on issues related to diagnosis and treatment.35
Only the University of Antioquia inMedellin has an
immunology program for medical residents, but,
as in other Latin American countries, these physi-
ciansprefer to specialize inothermedical areas, since
the financial return is greater.19 In 2010, the Jeffrey
Modell Foundation also established a research and
diagnostic center at the University of Antioquia in
Medellin.
Honduras
Honduras has two major health systems: public
health and social security, which provide coverage
for approximately 70% and 25% of the population,
respectively, while 5%of individuals have private in-
surance. PID patients in this country are diagnosed
after referral to major centers in Tegucigalpa or San
Pedro Sula, with access to these centers available to
all patients. The greatest challenges to diagnosis are
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laboratory access and the costs related to testing.
The only immunology laboratory able to support a
PID diagnosis is in Tegucigalpa.19
Mexico
In Mexico it is estimated that each year more than
4,000 children are born with PIDs and 250 will
present with severe forms. Mexico has specialized
centers for PID diagnosis and treatment in Mexico
City, Monterrey, and Guadalajara. Molecular and
genetic diagnosis for several PIDs can only be per-
formed at the Jeffrey Modell Diagnostic Center at
the National Institute of Pediatrics in Mexico City.
Treatment with IVIG is covered by the public health
system and is administered at no cost by public hos-
pitals and clinics, but there are no specific national
guidelines for IVIGadministration. InMexico, there
are several residency programs in allergy and im-
munology, with an emphasis on allergy. Only the
National Institute of Pediatrics in Mexico City has
a more balanced program in pediatric allergy and
clinical immunology, with an emphasis on PIDs.19
In summary, the conditions for PID diagnosis and
management are heterogeneous in Latin America.
Some countries have already joined the network to
advance this field in our continent. Some medi-
cal centers in these countries have residency and/or
postgraduate training programs in immunology.
One issue affecting government programs on PID
management is the lack of guidelines adapted for
Latin American countries. Immunologists gener-
ally followNorth American or European guidelines.
LASID is currently adapting those guidelines to the
Latin American reality, aiming to improve the man-
agement of patients with these diseases.
LASID activities
A major problem in developing countries has been
the lack of registries for rare diseases; because of
this the number of patients diagnosed does not re-
flect their actual prevalence. This problem is com-
pounded by the wide distribution of diagnostic
capabilities present in each country’s regions and
provinces, and PIDs are no exception (Table 2).
Moreover, the lack of standardized case definitions
makes it impossible to calculate rates of the healthy
population from this source, by only reporting pos-
itive cases without referencing population data.19
In Latin America, countries participating in
LAGID have published two reports about PIDs. The
first was in 1998 and included 1,428 patients from
eight countries (Argentina, Brazil, Chile, Colom-
bia, Costa Rica, Mexico, Paraguay, and Uruguay).
Predominantly, antibody deficiencies were reported
in 58% of patients, followed by cellular and anti-
body immunodeficiencies associated with other ab-
normalities in 18%, immunodeficiency syndromes
associated with granulocyte dysfunction in 8%,
phagocytic disorders in 9%, combined cellular and
antibody immunodeficiencies in 5%, and comple-
ment deficiencies in 2% of patients.36
A second report in 2007 documented 3,321 cases
from 12 Latin American countries (Argentina, Bo-
livia, Brazil, Chile, Colombia, Costa Rica, Ecuador,
Mexico, Peru, Paraguay, Uruguay, and Venezuela),
again with predominantly antibody deficiencies
in 53.2% of the patients, followed by other
Table 2.Current and expected PID prevalence in Latin America
Number inhabitants/ Expected number of
Countries million 2006 PID 2006 Frequency PID patients
Argentina 39.5 1,246 1:30,000 3,900
Brazil 186.1 790 1:235,000 18,600
Chile 16 279 1:58,000 1,600
Colombia 42.9 145 1:300,000 4,200
Mexico 106.2 399 1:265,000 10,600
Peru 27.9 17 1:1,600,000 2,800
The minimal incidence of PID cases in Latin American countries was estimated by calculating the average of cases in
2006. Each value was divided by the country’s birth rate in this period, and the result was multiplied by 100,000. From
Leiva, et al.24
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well-defined PID syndromes in 22.6%, combined
T and B cell immunodeficiency in 9.5%, phagocytic
disorders in 8.6%, disorders of immune dysregula-
tion in 3.3%, and complement deficiencies in 2.8%
of the patients. All countries that participated in the
first publication in 1998 reported an increase of PID
cases, ranging between 10% and 80%.24
These two reports highlight that, predominantly,
antibody deficiencies remain the main PIDs regis-
tered in Latin America, with similar trends in other
countries such as Australia,37,38 China,39,40 Egypt,41
France,42 Hong Kong,43 Iran,44–46 Italy,47 Kuwait,48
the Netherlands,49 Norway,50 Poland,51 Republic of
Ireland,52 Spain,53,54 Switzerland,55 Taiwan,56 Thai-
land,57 Tunisia,58 and the United States.59,60 How-
ever, other well-defined PID syndromes, such as
ataxia-telangiectasia, have been reported more fre-
quently, especially in Mexico and Central America.
A higher incidence of certain PIDs has also been
reported in other countries, such as India61 (phago-
cyte disorders) andTurkey62 (combinedT andB cell
immunodeficiencies).
The LASID online registry
The online PID registry program for Latin America
(LASID registry) was officially launched on April
28, 2009 in Sa˜o Paulo (Brazil) with the participa-
tion of 90 representatives from Argentina, Brazil,
Chile, Colombia, Honduras, and Mexico, and fac-
ulty members from the United States and Europe.
This registry was adapted from the ESID registry
and is currently supported by the Jeffrey Modell
Foundation (www.jmfworld.org.), CNPq-Brazil,
and the pharmaceutical companies Baxter, CSL
Behring, Octapharma, Grifols, and LFB. It is avail-
able at http://imunodeficiencia.unicamp.br:8080/
and as of September 2011, it contains in-
formation about 1,888 patients contributed by
40 centers from 11 Latin American countries
(Tables 1 and 3, Fig. 1).15,16,63 Up-to-date data
on this registry can be obtained on a regular
basis at http://imunodeficiencia.unicamp.br:8080/
estatistica mensal.html.
In April 2011, the LASID registry Program
Committee started three collaborative clinical epi-
demiological studies focusing initially on chronic
granulomatous disease, agammaglobulinemia, and
hyper-IgM syndrome. The preliminary results point
to some specific characteristics, such as the high
incidence of fungal infections in patients with
Table 3. Participating centers in the LASID registry
program
April May September
Countries 2009 2011 2011
Brazil 14 17 18
Argentina 5 6 7
Chile 1 1 1
Costa Rica 1 1
Colombia 1 1 1
Mexico 1 4 5
Honduras 1 1 1
Paraguay 0 1 1
Peru 0 3 3
Venezuela 0 1 1
Uruguay 1 1
Total 23 37 40
The number of LASID registry participating centers in-
creased to 40 centers in two years. Brazil, Argentina, and
Mexico represent the countries with themost referral cen-
ters. Centers > 100 cases in Argentina, Brazil, Mexico, and
Colombia.
X-linked hyper-IgM syndrome, and the incidence
of BCG adverse reactions in 17% of the patients
with chronic granulomatous disease. These results
were presented and discussed in detail during the
LASID meeting in Mexico in October 2011 and
should progress toward more comprehensive stud-
ies during 2012. Initiatives such as these aremotivat-
ing doctors to investigate and register their patients
in our online database.
On October 14, 2009, experts from Argentina,
Brazil, Chile, Colombia, Honduras, andMexico and
representatives of LAGID met in Cartagena de In-
dias in Colombia for the first time to discuss the
particular needs of each country with respect to
PIDs. This led to an initiative to publish the pro-
ceedings of this meeting and to date, LASID has
published four reports and proceedings; the first
two papers focused on the prevalence and char-
acteristics of PID patients in Latin America,24,36
and the third and fourth summarized deficiencies
in PID diagnosis and treatment in Latin America
and described features of an educational outreach
program, an immunology fellowship program, and
a laboratory network aimed at overcoming the cur-
rent deficiencies.19,20 More than compiling data, the
LASID registry brings an educational perspective,
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Figure 1. Distribution of PID among 1,888 patients from 12
countries in the new LASID registry. Predominantly antibody
deficiencies were reported in 59.7% patients, followed by other
well-defined PID syndromes in 17.3%, combined T and B cell
immunodeficiency in 10.1%, phagocytic disorders in 9.3%, dis-
orders of immune dysregulation in 1.1%, and complement de-
ficiencies in 2.5% of patients. From http://www.bragid.org.br.
as doctors must know first how to diagnose and
manage their patients before registering them.Thus,
registering patients will benefit doctors and pa-
tients.
Educational programs
To improve the diagnosis, medical care, and re-
search on PIDs in Latin America, the LASID Ad-
visory Board has established several initiatives that
include a CME program based on the PID warning
signs, a LASID fellowship program, a Latin Ameri-
can laboratory network, summer school programs,
and LASID scientificmeetings.19,20,64 Themain goal
of the educational programs is to increase the ca-
pability of pediatricians, general practitioners, and
some specialists to diagnose and manage patients
with PIDs, as well as to train laboratory profes-
sionals to establish and develop diagnostic tests for
PID patients. The fellowship program and summer
schools are targeted to the younger generations that
will multiply this network. It is expected that these
initiatives will lead to a higher number of diagnosed
patients, facilitating basic and clinical research.
LASID Summer School program
The LASID Summer School program has been an
opportunity to promote scientific interaction and
standardization of PID knowledge among differ-
ent member countries, as the educational resources
differ between participating countries.19,20 In 2006,
the first LAGID summer school took place in Sa˜o
Paulo (Brazil) based on the ESID and the Clinical
Immunology Society (CIS) models. Experts from
LAGID, ESID, CIS, and 36 students attended this
meeting and discussed the diagnosis of the major
PIDs in Latin America, IVIG therapy guidelines
and bone marrow transplantation, and a LAGID
communication network. Additional meetings took
place in 2008 in Temuco (Chile) and more recently
in 2010 in Bahia (Brazil) with 90 students from sev-
eral Latin American countries.
The LASID fellowship program
The LASID Advisory Board established the LASID
Fellowship program that will be starting in 2012.
This program is funded by Baxter Bioscience and
will include five fellows who will be selected on the
basis of the scientific merit of the proposals and the
commitment of the candidate to advance the PIDs
filed in Latin America.20 This program should help
motivate young professionals to pursue the field of
PID in Latin America and to serve as multipliers of
PID educational programs.
The creation of PID reference centers
Education and training are necessary for general
practitioners, pediatricians, and specialists from
other areas of medicine to ensure that they are
able to take care of PID patients. The first Jeffrey
Modell Center for Latin America was established in
April 2009 at the Federal University of Sa˜o Paulo-
UNIFESP. This center played a key role in educa-
tion, patient activities, and PID registry,65,66 and
now other centers sponsored as well by the Jeffrey
Modell Foundation have been established in Mex-
ico (2009), Colombia (2010), and Argentina (2011)
with similarpurposes. Inaddition, anetworkof clin-
ical centers and molecular diagnostic laboratories
was established in Chile in 2010. All of these centers
and networks have implemented educational pro-
grams and organize workshops in the main cities of
their countries to train physicians in the proper di-
agnostic approaches and treatments of patients with
PIDs. Simultaneously, these centers are developing
public relations campaigns in their areas of influ-
ence through radio, TV, and newspapers to bring
their messages to the general community as well. A
testimony to the success of this strategy is that in
Mexico, for example, more than 1,500 participants
have received basic training in PIDs, and patient
referrals to the Jeffrey Modell diagnostic center in
Mexico City have increased up to 40% in only one
year since the start of this program.Moreover, other
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Jeffrey Modell centers in Latin America are describ-
ing similar experiences.
Research development in PID in Latin
America
LAGIDwas created in 1993with the goals of spread-
ing educational and awareness programs, establish-
ing PID registries, and promoting annual scientific
meetings with the participation of well-recognized
international authorities in the PID field. This en-
vironment made possible important collaborations
among Latin American doctors who, in turn, in-
teracted with foreign investigators to create a net-
work that advanced scientific developments in PID
in Latin America. This collaboration has resulted
in several publications, beginning with the clinical
studies based on the LAGID registries.24–36
Research groups from Argentina, Brazil, Colom-
bia, Mexico, and Costa Rica have performed studies
in some well-known PIDs, such as CGD, agam-
maglobulinemia, hyper-IgM syndrome, Wiskott–
Aldrich syndrome, and ataxia-teleangiectasia,
resulting in several publications that pointed to par-
ticular phenotypes and novel genotypes.67–76 These
studies have contributed new insights about PID
clinical presentation and have had a positive im-
pact on the molecular diagnosis of PIDs. Specifi-
cally, these studies have shown that BCG complica-
tions are prevalent among SCID, T cell deficiency,
and CGD patients; that fungal infections are highly
prevalent among X-linked hyper-IgM patients; and
that ataxia-telangiectasia is exceptionally frequent in
Mexico and Costa Rica. Currently, Chile is building
a new diagnostic center at University La Frontera
that will work with research centers in Argentina,
Brazil, and Colombia. This strategy will strengthen
even more the interactions among the several Latin
American research centers. In addition, the Uni-
versity of Antioquia in Medellin has established a
national genomic sequencing center that promises
to bolster specific genomic studies in PIDs for the
region.
Latin American investigators have also been in-
volved in international studies leading to the discov-
ery of novel diseases and molecular defects. These
recent discoveries have led to major scientific ad-
vancements in PIDs that will likely have an im-
pact on the management of patients worldwide,
especially in Latin America where these diseases
are prevalent.77–84 The benefit of this interaction
reaches doctors and patients with chronic muco-
cutaneous candidiasis, Mendelian susceptibility to
mycobacterial diseases, antibody deficiencies, and
hyper-IgE syndrome. It is expected that these contri-
butions will encourage future generations of young
Latin American scientists to continue to develop
this research area in their own countries, stimulat-
ing professionals to stay and work in Latin America
where research has been growing significantly in re-
cent years.
In addition, some molecular discoveries and
mechanistic studies with clinical implications have
been achieved by Latin American groups not only
as collaborative partners of European or North
American research groups but also often as the
leading teams. The contributions include major
advancements in CVID, chronic granulomatous
disease and disorders of the NADPH oxidase
system, Mendelian susceptibility to mycobacterial
infections, anhidrotic ectodermal dysplasia with
immunodeficiency, hepatitis A, and complement
and autoimmune disorders.85–90 We believe that
research in Latin America will grow even more
after the implementation of the online PID registry.
Currently, there are ongoing studies on CGD,
agammaglobulinemia, hyper-IgM, a prospective
study on BCG adverse reactions, and the newborn
screening of PIDs. These clinical–epidemiological
studies will likely advance our understanding of
PID clinical science and influence novel molecular
and mechanistic studies and immunopathological
pathways that help explain the prevalent pheno-
types in Latin America. This should attract young
investigators to stay and develop leading PID
research teams in Latin America.
Concluding remarks
As the field of PIDs continues to grow, the coun-
tries of Latin America are undoubtedly making
their own contribution. Nevertheless, there are
challenges ahead that are not unusual in other coun-
tries around the world, even if individual coun-
tries have come to their own solutions. Basic as-
pects, such as improved diagnosis, availability of
treatments, and government support, remain at the
core of critical issues concerning PIDs that must
be resolved. Moreover, issues such as incidence
and prevalence and variations in phenotypes and
molecular genotypes—increasingly recognized as
unique to particular regions—must be taken into
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account in Latin America in order to provide accu-
rate information about how these diseases behave
in this part of the world. To provide these solutions,
LASID has been working recently to consolidate its
agenda by establishing PID educational programs,
registries, referral centers, and a network of labora-
tories throughout the continent. These initiatives
have the support of other organizations such as
ESID, the Jeffrey Modell Foundation, and CIS to
name a few, providing an example of how the union
of people brings synergy to the ideas. We are hope-
ful that they will have a positive impact on a greater
number of diagnosed patients, increase scientific
developments, expand professional networks, and
generate greater awareness about PIDs.
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